Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Former Michigan quarterback J.J. McCarthy has been a name frequently mentioned since the Minnesota Vikings’ Wild Card loss to the Los Angeles Rams. McCarthy wasn’t on the field for the 27-9 ...

DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on this site. This service is intended for adult audiences. No guarantees are made ...

This collaboration unites Novo Nordisk’s deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology with the aim to discover tissue targeting ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will summarize the bulls’ thesis on NVO. The company’s shares were trading ...

Gift 5 articles to anyone you choose each month when you subscribe. The head of Optus’ customer success business, Maurice McCarthy, has resigned, marking the first major executive exit under new ...

so if they’re coveting an elite backfield mate for Jones and quarterback J.J. McCarthy, they’ll need to consider it on Day 1. Fans might roll their eyes at going running back in Round 1.

Vikings Urged To Re-Sign Aaron Jones To Support JJ McCarthy As a result, Brad Gagnon of Bleacher Report believes that the Vikings needs to re-sign the former Pro Bowler this offseason.

The Minnesota Vikings selected former Michigan quarterback JJ McCarthy in the first round of last year's draft only to watch him miss his rookie season after suffering a torn meniscus in his right ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,000.00. The company’s shares closed yesterday at DKK657.07.